Skip to main
OPK
OPK logo

OPKO Health (OPK) Stock Forecast & Price Target

OPKO Health (OPK) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 45%
Buy 36%
Hold 18%
Sell 0%
Strong Sell 0%

Bulls say

OPKO Health's recent strategic transaction is viewed favorably as it sharpens the company's focus on drug development while also enhancing its balance sheet. The company reported a Q4 2024 revenue of $183.6 million, reflecting a 0.9% year-over-year growth, which surpassed projections and indicates solid operational performance. Furthermore, management's commitment to improving BioReference's productivity and its aim for profitability by 2025, alongside a strengthened cash position and a realized gain from asset sales, collectively contribute to a positive financial outlook for the company.

Bears say

OPKO Health Inc reported a significant 17% year-over-year decline in diagnostics services revenue, totaling $103.1 million, primarily driven by reduced clinical test volumes linked to the sale of certain BioReference assets. For the full year of 2024, total revenue declined by 17% to $713.1 million, reflecting persistent challenges in both its diagnostics and pharmaceutical segments, with pharmaceutical products revenue decreasing by 13% to $37.4 million due to unfavorable foreign currency exchange rates. Additional risks that contribute to the negative outlook include potential lower-than-expected growth in diagnostics services, challenges in developing new pharmaceuticals, and fluctuations in sales due to competition and market dynamics.

OPKO Health (OPK) has been analyzed by 11 analysts, with a consensus rating of Buy. 45% of analysts recommend a Strong Buy, 36% recommend Buy, 18% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of OPKO Health and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About OPKO Health (OPK) Forecast

Analysts have given OPKO Health (OPK) a Buy based on their latest research and market trends.

According to 11 analysts, OPKO Health (OPK) has a Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11.07, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11.07, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

OPKO Health (OPK)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.